Monopar Therapeutics MNPR Enterprise value

Enterprise value at other companies

Bristol-Myers SquibbBMY

$152.27B+14.9%

Eli LillyLLY

$1.12T+51.8%

Bausch Health CompaniesBHC

$21.45B-5.6%

Ultragenyx PharmaceuticalRARE

$1.83B-51.1%

Wave Life SciencesWVE

$793.44M-9.4%

Prime MedicinePRME

$717.81M+114%

FAQ

What is Monopar Therapeutics's enterprise value?

Monopar Therapeutics (MNPR) reported enterprise value of $314.35M in Q1 2026.

How has Monopar Therapeutics's enterprise value changed year-over-year?

Monopar Therapeutics's enterprise value increased by 72.3% year-over-year, from $182.49M to $314.35M.

What is the long-term trend for Monopar Therapeutics's enterprise value?

Over 2 years (2022 to 2025), Monopar Therapeutics's enterprise value has grown at a 308.2% compound annual growth rate (CAGR), from $22.49M to $374.78M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.